IRONMAN Trial Effectiveness of Intravenous Iron Treatment Versus Standard Care in Patients With Heart Failure and Iron Deficiency A randomized, open-label, blinded-endpoint trial Objective:To evaluate the safety and efficacy of ferric derisomaltose on cardiovascular outcomes among patients with heart failure … Read More
heart failure
DEA-HF Trial: Diuretics Regimen in CHF
The infographic details findings from the DEA-HF study, which was designed to evaluate the efficacy and safety of three different diuretic treatment regimens in patients with ambulatory congested heart failure (CHF). The study was conducted in a prospective, randomized, open-label, … Read More
REDUCE LAP-HF II: Atrial Shunt Device in HFpEF and HFmEF
Insights from the REDUCE LAP-HF II Trial: Atrial Shunt Devices in Heart Failure Management The REDUCE LAP-HF II Trial, published in 2022, was a significant randomized, blinded, sham-controlled trial aiming to enhance the treatment for patients with heart failure. It … Read More
DAPA-MI Trial: Dapagliflozin in MI
DAPA-MI Trial: Dapagliflozin in MI? The DAPA-MI Trial, as reported in the New England Journal of Medicine in 2023, was a randomized, double-blind clinical trial designed to assess the safety and efficacy of dapagliflozin, a medication typically used to treat … Read More
CASTLE HTx Trial: Ablation in HF and AFib
The CASTLE HTx trial, as published in the New England Journal of Medicine in 2023, was a single-center, open-label trial that aimed to determine the potential therapeutic effect of catheter ablation for symptomatic atrial fibrillation (AF) in patients with end-stage … Read More
HEART-FID Trial: Iron in Heart Failure
The HEART-FID trial, as published in the New England Journal of Medicine in 2023, was a randomized, double-blind, placebo-controlled study designed to determine the efficacy and safety of intravenous ferric carboxymaltose (FCM) in treating patients with heart failure with reduced … Read More
ECLS-SHOCK Trial: Extracorporeal Life Support in Cardiogenic Shock
The ECLS-SHOCK trial, as reported in the New England Journal of Medicine in 2023, was a multicenter, parallel, randomized controlled trial designed to evaluate the efficacy of extracorporeal life support (ECLS) in patients with acute myocardial infarction (MI) complicated by … Read More
A New Frontier in Heart Failure Management: A Comprehensive Review of Landmark Clinical Trials on SGLT2 Inhibitors
Explore the transformative clinical trials that have solidified the role of SGLT2 inhibitors in heart failure management and their potential to redefine the treatment landscape. Introduction Heart failure is a complex clinical syndrome associated with significant morbidity and mortality. In … Read More
The Data Behind HFpEF Management: Landmark Clinical Trials on Heart Failure with Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFpEF) is a complex and increasingly prevalent form of heart failure, accounting for nearly half of all heart failure cases. Despite its significance, HFpEF remains a challenging condition to manage and treat, as effective … Read More
MADIT-CRT Trial Summary: CRT in HF
2009 MADIT-CRT TRIAL Cardiac-Resynchronization Therapy for the prevention of heart-failure events multicenter, open-label, randomized controlled trial Objective: To determine whether cardiac-resynchronization therapy with implantable cardioverter-defibrillator (CRT-ICD) would reduce the risk of death or heart-failure events in M patients with mild … Read More